Cytokinetics Inc CYTK

Healthcare Biotechnology

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporate...

NDAQ:CYTK - Post by User

Cytokinetics Inc

<< Previous

Bullboard Posts

(4)
•••

Post by AviseAnalyticson Feb 08, 2022 8:58am

182 Views

Post# 34407915

5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS

$CYTK $ADGI $PHAT $AGIO $ICPT

Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table.

The covered Companies have major upcoming catalysts such as an impending FDA approval, drug launch, data readouts, initiation of clinical trials and IND submission to look forward to.

Learn More:
https://www.aviseanalytics.com/5-biotech-stocks-with-major-upcoming-catalysts/

<< Previous

Bullboard Posts

Quantum computing: Why investors should be paying attention now